

# SyrSpend® SF Superior suspending technology



www.fagron.gr

# SyrSpend® SF

SyrSpend<sup>®</sup> SF is an innovative vehicle range for the compounding of oral liquid dosage forms. Based on food starch, SyrSpend<sup>®</sup> SF's superior suspending properties provide consistent, individual dosing throughout treatment.

The excellent compatibility with a broad range of active pharmaceutical ingredients (APIs) and meticulous ingredient safety make SyrSpend® SF highly suitable for compounding safe and stable customized medication. SyrSpend® SF is quick and easy to compound with and provides pharmaceutical stability and dosage consistency with each preparation. Its light texture, safe ingredients, and neutral taste results in treatment that is comfortable and easy to swallow for all patient groups, from neonates to the elderly.

# **Benefits of Syrspend® SF**

## **Active Suspending Technology**

Unique starch-based technology that allows for the preparation of a homogeneous suspension to guarantee dosage safety throughout treatment.<sup>1</sup>

### **Ingredient safety**

SyrSpend<sup>®</sup> SF's meticulous ingredient safety helps minimize side effects and allergic reactions.

### Proven compatibility

Supported by multiple scientific stability studies, SyrSpend® SF is highly compatible with a broad range of APIs.

## **Patient comfort**

Easy to swallow, with a light texture and no medicinal aftertaste, SyrSpend<sup>®</sup> SF is number one for patient comfort and enhanced patient compliance.

### **High efficiency**

Convenient, easy-to-use oral suspending vehicles and convenience packs facilitate immediate compounding.

## **Exceptional quality**

Manufactured in compliance with the highest pharmaceutical standards, SyrSpend® SF supports optimal solutions for your patients.

# Active suspending technology

SyrSpend<sup>®</sup> SF employs active suspending technology: the superior pseudoplasticity and thixotropy features of the vehicles provide high accuracy and dosage consistency throughout treatment. With just a few shakes, the pseudoplasticity of SyrSpend<sup>®</sup> SF ensures rapid redispersion of the API(s) in the compounded

suspension, allowing for ongoing low effort rehomogenization. Left to stand, the suspension thickens due to thixotropic properties, keeping the API(s) safely suspended and preventing the formation of an irreversible sediment cake, even when left untouched for up to a month.<sup>1</sup>

# Ingredient safety

SyrSpend<sup>®</sup> SF is suitable for vulnerable patient groups, including pediatric, elderly, and chronic patients and those fed by a (naso)gastric tube.

Based on the latest WHO, EMA, ANVISA, and FDA guidelines, SyrSpend® SF contains only safe ingredients, minimizing toxicological effects and allergic reactions. The absence of lactose combined with low osmolality (<50 mOsmol/kg) minimizes gastrointestinal side effects. All SyrSpend® SF vehicles are sugar free, suitable for small children, and compatible with ketogenic diets.

## SyrSpend® SF is free of:

- Benzyl alcohol
- Carrageenan
- Colorants
- Dextrose
- Ethanol
- Glycerin
- Lactose

- Parabens
- Propylene glycol
- Sorbitol
- Sucrose
- Xylitol
- Common food allergens


# Proven compatibility

Constant investments in performing forced-degradation stability indicating HPLC at independend laboratories has made SyrSpend® SF the best studied vehicle worldwide. To date, 140 different compatibility studies show that SyrSpend® SF is compatible with a broad range of APIs.

All combinations that have been scientifically studied for chemical, physical, and microbiological stability are included in the SyrSpend® SF compatibility table and Compounding Matters formulations database.

# Always the right dose

In a recent study, SyrSpend<sup>®</sup> SF has shown to be capable of delivering the right dose in the more than 105 different APIs studied. In total, 6414 samples were analysed by HPLC-UV and in all cases, they were well within the criteria for Content Uniformity as defined by the different pharmacopoeias. This study therefore indicates that SyrSpend<sup>®</sup> SF not only allows for dosing flexibility, but also provides maximum dosing safety.<sup>2,3</sup>



# SyrSpend<sup>®</sup> SF

SyrSpend<sup>®</sup> SF provides convenient, safe, and efficient vehicles for the preparation of oral liquid dosage forms. All products are taste-masking with a pleasant, sweet taste and available in neutral flavor for easy acceptance by the patient. Compatible with an extensive range of APIs, you can choose the most suitable product for compounding with both acid and alkaline options.

#### EASY TO USE

SY TO USE		CONVENIENCE PACKS FOR MAXIMUM EFFICIENCY	
	<ul> <li>SyrSpend<sup>®</sup> SF PH4 (liquid)</li> <li>Gently preserved with &lt;0.1% sodium benzoate</li> <li>Buffered to pH 4.2 for maximum compatibility</li> <li>Also available in cherry flavor</li> <li>500 ml suspension</li> </ul>	Pack Pack Pack Sy red dis pr Af or tip pr cco cco cco cco cco cco cco	pend® SF convenience s s contain: rrSpend® SF (dry, for constitution) in a validated spensing container e-weighed PI powder al syringe o extender ess-in bottle adapter ompounding instructions eaning instructions for the syringe o extender
ECTCOMPO	OUNDING IN DISPENSING CONTAINER		
	SvrSpand® SE DH1 NEO	SurS	nend® SE Alka

#### DIRE



#### SyrSpend® SF PH4 NEO (dry, for reconstitution)

- Buffered to pH 4.2 for maximum compatibility
- Gently preserved with 0.2% Sorbic acid ٠
- Pre-weighed powder to make 100 ml or 200 ml suspensions



#### SyrSpend<sup>®</sup> SF Alka (dry, for reconstitution)

- Buffered to pH >7 for acid-labile APIs
- Preservative free •
- Pre-weighed powder to make 100 ml or 200 ml suspension

Disclaimer: While a great deal of effort has been spent to ensure the accuracy of the dosages and formulations contained herein, no claims are made as to the uses, safety, efficacy or bioavailability of these recommendations. The content of this table cannot be construed as being a (medical) advice, recommendation or opinion. Medical professionals, doctors and compounding pharmacists using this information are advised to do so solely if appropriate in their own professional opinion and judgement. Fagron does not accept and cannot be held responsible or liable in any case for the formulation or information contained herein.

#### References

- 1. Visser JC et al. Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations. International Journal of Pharmaceutical Compounding;22(3):247-251.
- 2. Dijkers, E, Nanhekhan V, Thorissen V and Hudson P. Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules. International journal of pharmaceutical compounding 21 2 (2017): 171-175.
- 3. Dijkers ECF, Polonini H and Ferreira A. Content Uniformity of Extemporaneous Compounded Suspensions. Abstract accepted for the EAHP 2020 congress Hospital Pharmacy 5.0 - the future of patient care.

#### **Fagron Hellas** 12 km N.R. Trikala - Larisa P.C. 42100, P.O. Box 32 Trikala, Greece

T +30 24310 83633-5 F +30 24310 83615 www.fagron.gr

